Ubiflox 5mg Tablets for Cats and Dogs

Main information

  • Trade name:
  • Ubiflox 5mg Tablets for Cats and Dogs
  • Pharmaceutical form:
  • Tablet
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Ubiflox 5mg Tablets for Cats and Dogs
    Austria
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • marbofloxacin
  • Therapeutic area:
  • Cats, Dogs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0434/001
  • Authorization date:
  • 21-11-2012
  • EU code:
  • UK/V/0434/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Issued:May2013

AN:01886/2011

Page1of5

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Ubiflox5mgtabletsforcatsanddogs

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachtabletcontains:

Activesubstance:

Marbofloxacin …….5mg

Excipients:

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Tablets.

Lightbrownishyellow,round,biconvex,marbletabletswithbevellededgesandwithpossible

darkandwhitespots,scoredononeside.

Thetabletscanbedividedintohalves.

4. CLINICALPARTICULARS

4.1 Targetspecies

Catsanddogs.

4.2 Indicationsforuse,specifyingthetargetspecies

Treatmentofinfectionscausedbystrainsofmicroorganismssusceptibletomarbofloxacin.

Indogs:

skinandsofttissueinfections(skinfoldpyoderma,impetigo,folliculitis,furunculosis,

cellulitis);

urinarytractinfections(UTI)associatedornotwithprostatitisorepididymitis;

respiratorytractinfections.

Incats:

skinandsofttissueinfections(wounds,abscesses,phlegmons);

upperrespiratorytractinfections.

4.3 Contraindications

Donotuseindogsagedlessthan12months,orlessthan18monthsforexceptionallylarge

breedsofdogs,suchasGreatDanes,Briard,Bernese,BouvierandMastiffs,withalonger

growthperiod.

Donotuseincatsagedlessthan16weeks.

Donotuseinanimalswithknownhypersensitivitytomarbofloxacinorother

(fluoro)quinolonesortoanyoftheexcipientsoftheproduct.

Issued:May2013

AN:01886/2011

Page2of5

4.4 Specialwarningsforeachtargetspecies

AlowurinarypHcouldhaveaninhibitoryeffectontheactivityofmarbofloxacin.Pyoderma

occursmostlysecondarytoanunderlyingdisease,thus,itisadvisabletodeterminethe

underlyingcauseandtotreattheanimalaccordingly.

4.5 Specialprecautionsforuse

Specialprecautionsforuseinanimals

Highdosesofsomefluoroquinolonesmayhaveepileptogenicpotential.Cautioususeis

recommendedindogsandcatsdiagnosedassufferingfromepilepsy.However,atthe

therapeuticrecommendeddosage,nosevereside-effectsaretobeexpectedindogsand

cats.Inparticular,nolesionsofthearticularjointswereencounteredinclinicalstudiesatthe

recommendeddoserate.

Officialandlocalantimicrobialpoliciesshouldbetakenintoaccountwhentheveterinary

medicinalproductisused.Fluoroquinolonesshouldbereservedforthetreatmentofclinical

conditionswhichhaverespondedpoorly,orareexpectedtorespondpoorlytootherclasses

ofantimicrobials.

Wheneverpossible,useoffluoroquinolonesshouldbebasedonsusceptibilitytesting.

UseoftheproductdeviatingfromtheinstructionsgivenintheSPCmayincreasethe

prevalenceofbacteriaresistanttothe(fluoro)quinolonesandmaydecreaseeffectivenessof

treatmentwithotherquinolonesduetothepotentialforcross-resistance.

Specialprecautionstobetakenbythepersonadministeringtheveterinarymedicinal

producttoanimals

Peoplewithknownhypersensitivityto(fluoro)quinolonesshouldavoidusingthisproduct.

Incaseofaccidentalingestionseekmedicalattentionandshowproductlabeland/or

packageleaflettothedoctor.

Washhandsafteruse.

4.6Adversereactions(frequencyandseriousness)

Mildsideeffectssuchasvomiting,softeningoffaeces,modificationofthirstortransient

increaseinactivitymayoccasionallyoccur.Thesesignsceasespontaneouslyaftertreatment

anddonotnecessitatecessationoftreatment.

4.7Useduringpregnancy,lactationorlay

Studieslaboratoryanimals(rat,rabbit)showednoembryotoxicity,teratogenicityand

maternotoxicitywithmarbofloxacinattherapeuticdoses.Howevernospecificstudieshave

beencarriedoutinpregnantorlactatingcatsanddogs.Therefore,intheseclassesof

animals,useonlyaccordingtothebenefit/riskassessmentbytheresponsibleveterinarian.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Fluoroquinolonesareknowntointeractwithorallyadministeredcations(Aluminium,Calcium,

Magnesium,Iron).Insuchcases,thebioavailabilityofmarbofloxacinmaybereduced.

Concurrentadministrationoftheophyllineproductsmaybefollowedbyinhibitedtheophylline

clearance.

Issued:May2013

AN:01886/2011

Page3of5

4.9 Amountstobeadministeredandadministrationroute

Fororaladministration.

Therecommendeddoserateis2mg/kg/day(1tabletfor2.5kgperday)insingledaily

administration.Whereappropriate,indogsonly,theuseofcombinationsofwholeorhalf

tabletsofdifferentstrengths(5mg,20mgor80mg)willallowaccuratedosing.

Animalbodyweight

(kg) Numberoftablets

(5mgstrength) Approx.dosagerange

(mg/kg)

1 –1.5 0.5 1.7 –2.5

>1.5 –2.5

1 2.0 –3.3

>2.5 –3.5 1.5 2.1 –3.0

>3.5 –5.0 2 2.0 –2.9

>5.0 –7.0 3 2.1 –3.0

>7.0 –9 4 2.2 –2.9

Toensureacorrectdosagebodyweightshouldbedeterminedasaccuratelyaspossibleto

avoidunderdosing.

Durationoftreatment

Dogs:

inskinandsofttissueinfections,treatmentdurationisatleast5daysanddependingonthe

courseofthedisease,itmaybeextendedupto40days.

inurinarytractinfections,treatmentdurationisatleast10daysanddependingonthecourse

ofthedisease,itmaybeextendedupto28days.

inrespiratoryinfections,treatmentdurationisatleast7daysanddependingonthecourseof

thedisease,itmaybeextendedupto21days.

Cats:

forskinandsofttissueinfections(wounds,abscesses,phlegmons)treatmentdurationis3to

5days.

forupperrespiratoryinfectionstreatmentdurationis5days.

4.10 Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Overdosagemaycauseacutesignsintheformofneurologicaldisorders,whichshouldbe

treatedsymptomatically.

4.11Withdrawalperiod(s)

Notapplicable.

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Antibacterialsforsystemicuse,Fluoroquinolones,

ATCvetcode:QJ01MA93

5.1 Pharmacodynamicproperties

Marbofloxacinisasynthetic,bactericidalantimicrobial,belongingtothefluoroquinolone

groupwhichactsbyinhibitionofDNAgyraseandoftopoisomeraseIV.Itiseffectiveagainst

awiderangeofGrampositivebacteria(includingStreptococciandinparticular

Staphylococci)andGramnegativebacteria(Escherichiacoli,Citrobacterfreundii,Proteus

Issued:May2013

AN:01886/2011

Page4of5

spp.,Klebsiellaspp,Shigellaspp.,Pasteurellaspp.,Pseudomonasspp.)aswellas

Mycoplasmaspp.

Asecondaryliteraturereportofmicrobiologicalsusceptibilitydatawhosesourceincludedtwo

Europeanfieldsurveys,eachinvolvinghundredsofcanineandfelinepathogenssusceptible

tomarbofloxacin,waspublishedin2009.

Microorganism MIC(µg/ml)

Staphylococcus

intermedius 0.23-0.25

Escherichiacoli 0.125-0.25

Pasteurellamultocida 0.04

Pseudomonasaeruginosa 0.94

Susceptibilitybreakpointshavebeendeterminedas ≤1µg/mlforsensitive,2µg/mlfor

intermediateand≥4µg/mlforresistantbacterialstrains.

Marbofloxacinisnotactiveagainstanaerobes,yeastorfungi.Casesofresistancehave

beenobservedinStreptococcus.

Resistancetofluoroquinolonesoccursbychromosomalmutationwiththreemechanisms:

decreaseofthebacterialwallpermeability,expressionofeffluxpumpormutationof

enzymesresponsibleformoleculebinding.

5.2 Pharmacokineticparticulars

Afteroraladministrationindogsandcatsattherecommendeddoseof2mg/kg,

marbofloxacinisreadilyabsorbedandreachesmaximalplasmaconcentrationsof1.5µg/ml

within2hours

Itsbioavailabilityiscloseto100%.

Itisweaklyboundtoplasmaproteins(lessthan10%),extensivelydistributedandinmost

tissues(liver,kidney,skin,lung,bladder,digestivetract)itachieveshigherconcentrations

thaninplasma.Marbofloxaciniseliminatedslowly(t½ß=14hindogsand10hincats)

predominantlyintheactiveforminurine(2/3)andfaeces(1/3).

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Lactosemonohydrate

Povidone(K90)

Yeastpowder

Meatflavour

Crospovidone

Castoroil,hydrogenated

Silica,ColloidalAnhydrous

Magnesiumstearate

6.2Incompatibilities

Notapplicable.

6.3Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:2years

Issued:May2013

AN:01886/2011

Page5of5

Shelflifeofhalf-tablets:5days.

6.4.Specialprecautionsforstorage

Storeintheoriginalpackageinordertoprotectfromlight.

Thisveterinarymedicinalproductdoesnotrequireanyspecialtemperaturestorage

conditions.

6.5Natureandcompositionofimmediatepackaging

Polyvinylchloride-aluminium-orientedpolyamide/Aluminiumcoldformedblistercontaining10

tablets.

Boxeswiththeinstructionleafletwith10tabletsand100tablets.

Notallpacksizesmaybemarketed.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinalproductor

wastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuchveterinary

medicinalproductsshouldbedisposedofinaccordancewithlocalrequirements.

7. MARKETINGAUTHORISATIONHOLDER

KRKA,d.d.,Novomesto

Šmarješkacesta6

8501Novomesto

Slovenia

8. MARKETINGAUTHORISATIONNUMBER

Vm01656/4050

9. DATEOFFIRSTAUTHORISATION

10May2013

10. DATEOFREVISIONOFTHETEXT

May2013

PROHIBITIONOFSALE,SUPPLYAND/ORUSE

Notapplicable.

Approved: 10/05/2013

5-12-2018

Columbia River Natural Pet Foods Inc. Recalls Cow Pie Fresh Frozen Meats for Dogs and Cats Because of Possible <em>Listeria monocytogenes</em> Health Risk

Columbia River Natural Pet Foods Inc. Recalls Cow Pie Fresh Frozen Meats for Dogs and Cats Because of Possible <em>Listeria monocytogenes</em> Health Risk

Columbia River Natural Pet Foods of Vancouver, WA is voluntarily recalling 933 packages of Cow Pie fresh frozen meats for dogs and cats, produced in August 2017, because it has the potential to be contaminated with Listeria monocytogenes

FDA - U.S. Food and Drug Administration

4-12-2018

FDA Approves Pexion for Treating Noise Aversion in Dogs

FDA Approves Pexion for Treating Noise Aversion in Dogs

The U.S. Food and Drug Administration announced today that its Center for Veterinary Medicine has approved Pexion (imepitoin tablets) to treat noise aversion in dogs. Dogs with noise aversion are sensitive to loud noises such as fireworks, street/traffic noises, and gun shots.

FDA - U.S. Food and Drug Administration

26-11-2018

FDA Welcomes Grant Applications for Animal Drugs for Minor Uses and Minor Species

FDA Welcomes Grant Applications for Animal Drugs for Minor Uses and Minor Species

The U.S. Food and Drug Administration today announced an open period for applications for grants to support the development of new animal drugs intended to treat uncommon diseases (minor uses) in major species (horses, dogs, cats, cattle, pigs, turkeys and chickens) or to treat minor species.

FDA - U.S. Food and Drug Administration

7-6-2018

Prevent Heartworms in Dogs, Cats, and Ferrets Year-Round

Prevent Heartworms in Dogs, Cats, and Ferrets Year-Round

Heartworm disease can be fatal to pets, but it is also preventable. Learn more about the dangers of heartworm disease and the importance of year-round prevention.

FDA - U.S. Food and Drug Administration